article thumbnail

2023-2024 COVID-19 Vaccine Efficacy Wanes Over Time

Drug Topics

A new study reveals the waning effectiveness of 2023-2024 COVID-19 vaccines, highlighting the need for ongoing vaccinations and pharmacist involvement.

Vaccines 530
article thumbnail

Pneumococcal Vaccine Rates Low Despite Updated Recommendations

Drug Topics

In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. Of those, 38% had evidence of pneumococcal vaccination prior to January 2022.

Vaccines 342
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

PharmaVoice

Today, we’re speaking to Simone Steiner, Transgene’s new chief technology officer, about how the company is transitioning from early- to late-stage testing and advancing its manufacturing capabilities Oncology vaccines are gaining traction in the clinic as potential game changing treatments for cancer.

Vaccines 244
article thumbnail

Flu Vaccines Are a Go

Pharmacy Times

The shift away from thimerosal may increase the use of single-dose syringes, impacting vaccination practices in various healthcare settings. ACIP's recommendations are increasingly significant for pharmacies, influencing vaccination planning, billing, and patient care activities.

Vaccines 100
article thumbnail

Childhood vaccination coverage was falling across the globe even before Covid

STAT

Childhood vaccination coverage has made leaps since 1980. That is according to a study published in The Lancet Tuesday, which found stagnation and wide variation in childhood vaccination rates since 2010. But progress has significantly slowed in the last two decades.

Vaccines 136
article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.

article thumbnail

Osivax publishes phase 2a results supporting dual flu vaccine approach

Pharma Times

The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses.